目的 評價脂質(zhì)體多柔比星（脂質(zhì)體阿霉素）治療惡性腫瘤的臨床療效及安全性。方法 計算機檢索中國學術(shù)文獻總庫（CNKI）、萬方數(shù)字化期刊庫、中國生物醫(yī)學文獻數(shù)據(jù)庫（CBM）、維普中文科技期刊數(shù)據(jù)庫（VIP），PubMed數(shù)據(jù)庫、Embase數(shù)據(jù)庫和Cochrane Library數(shù)據(jù)庫，脂質(zhì)體多柔比星治療惡性腫瘤的中英文隨機對照試驗，檢索年限從建庫至2017年1月。采用RevMan 5.3軟件對各效應指標進行Meta分析。結(jié)果 納入23篇RCT文獻，計5 546名惡性腫瘤患者。Meta分析結(jié)果顯示：治療前后臨床療效I²=63%、OR=1.14[1.02，1.27]，P=0.002；兩組化療后心臟毒性不良事件I²=0%，OR=0.18[0.10，0.33]，P<0.000 01；脫發(fā)不良事件I²=77%，OR=0.24[0.17，0.35]，P<0.000 01；神經(jīng)毒性不良事件I²=46%，OR=0.65[0.42，0.99]，P=0.05。結(jié)論 脂質(zhì)體多柔比星治療惡性腫瘤的臨床療效優(yōu)于其他化療方案，且毒副作用低，尤其在改善心臟毒性、脫發(fā)等不良事件方面明顯優(yōu)于其他化療方案。

Objective To evaluate the clinical efficacy and safety of liposomal doxorubicin in the treatment of cancer. Methods The randomized controlled trials of liposomal doxorubicin in treatment of cancer were searched from Chinese academic literature database (CNKI), Wanfang digital journals, Chinese biomedical literature database (CBM), Chinese scientific journal database (VIP), PubMed database, Embase database and The Cochrane Library database. Data were collected from establishment of the database to January 2017 and the each index was analyzed by Meta-analysis with RevMan 5.3 software. Results A total of 5546 patients with malignant tumors were included in the RCT literature of the 23 articles. The Meta analysis results showed that the analysis on clinical curative effect before and after treatment:I²=63%, OR=1.14[1.02, 1.27], P=0.002; the analysis on safety evaluation of Meta of two groups of cardiac toxicity adverse events:I²=0%, OR=0.18[0.10, 0.33], P<0.00001; I²=77%, OR=0.24[0.17, 0.35]; the analysis on alopecia adverse events:P<0.000 01; I²=46% OR=0.65[0.42, 0.99], the ananlysis on neurotoxic adverse events:P=0.05. Conclusion The clinical efficacy of liposomal doxorubicin in the treatment of malignant tumors is better than other chemotherapy regimens, with low side effects, and is especially significantly better than other chemotherapy regimens in the improvement of cardiac toxicity, neurotoxicity, alopecia and other adverse events.